Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and Death
Open Access
- 1 March 2014
- journal article
- Published by Annals of Family Medicine in Annals of Family Medicine
- Vol. 12 (2), 121-127
- https://doi.org/10.1370/afm.1601
Abstract
PURPOSE Azithromycin use has been associated with increased risk of death among patients at high baseline risk, but not for younger and middle-aged adults. The Food and Drug Administration issued a public warning on azithromycin, including a statement that the risks were similar for levofloxacin. We conducted a retrospective cohort study among US veterans to test the hypothesis that taking azithromycin or levofloxacin would increase the risk of cardiovascular death and cardiac arrhythmia compared with persons taking amoxicillin. METHODS We studied a cohort of US veterans (mean age, 56.8 years) who received an exclusive outpatient dispensation of either amoxicillin (n = 979,380), azithromycin (n = 594,792), or levofloxacin (n = 201,798) at the Department of Veterans Affairs between September 1999 and April 2012. Azithromycin was dispensed mostly for 5 days, whereas amoxicillin and levofloxacin were dispensed mostly for at least 10 days. RESULTS During treatment days 1 to 5, patients receiving azithromycin had significantly increased risk of death (hazard ratio [HR] = 1.48; 95% CI, 1.05–2.09) and serious arrhythmia (HR = 1.77; 95% CI, 1.20–2.62) compared with patients receiving amoxicillin. On treatment days 6 to 10, risks were not statistically different. Compared with patients receiving amoxicillin, patients receiving levofloxacin for days 1 to 5 had a greater risk of death (HR = 2.49, 95% CI, 1.7–3.64) and serious cardiac arrhythmia (HR = 2.43, 95% CI, 1.56–3.79); this risk remained significantly different for days 6 to 10 for both death (HR = 1.95, 95% CI, 1.32–2.88) and arrhythmia (HR = 1.75; 95% CI, 1.09–2.82). CONCLUSIONS Compared with amoxicillin, azithromycin resulted in a statistically significant increase in mortality and arrhythmia risks on days 1 to 5, but not 6 to 10. Levofloxacin, which was predominantly dispensed for a minimum of 10 days, resulted in an increased risk throughout the 10-day period.Keywords
This publication has 16 references indexed in Scilit:
- Use of Azithromycin and Death from Cardiovascular CausesThe New England Journal of Medicine, 2013
- Antimicrobial agents-associated with QT interval prolongation.Current Drug Safety, 2010
- Azithromycin‐Induced Torsade De PointesPacing and Clinical Electrophysiology, 2007
- Überlebenszeitanalyse: Die Cox-RegressionDeutsche Medizinische Wochenschrift (1946), 2007
- p Value fetishism and use of the Bonferroni adjustmentEvidence-Based Mental Health, 2007
- A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo studyStatistics in Medicine, 2006
- Accuracy and completeness of mortality data in the Department of Veterans AffairsPopulation Health Metrics, 2006
- Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform EffectAmerican Journal of Epidemiology, 2005
- A case of QT-interval prolongation precipitated by azithromycin.2003
- QT Prolongation Associated with Azithromycin/Amiodarone CombinationPacing and Clinical Electrophysiology, 2001